The International Myeloma Working Group (IMWG) has published a consensus statement providing practical recommendations for managing myeloma patients who develop second primary malignanices (SPMs). Published in the Annals of Oncology, the group reviewed the latest evidence of possible host-, disease- and treatment-related risk factors for the development of SPMs in myeloma patients. They recommend that…
Identification of pathway-based prognostic gene signatures in patients with multiple myeloma. Zamani-Ahmadmahmudi M et al. Transl Res. 2017 May 9. pii: S1931-5244(17)30041-5. doi: 10.1016/j.trsl.2017.05.001. [Epub ahead of print]. Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy. Łuczak M, Kubicki T et al. Pol Arch Intern Med. 2017 May 25. doi: 10.20452/pamw.4032. [Epub ahead of…
Incidence, characteristics and outcome of solitary plasmacytoma and plasma cell leukemia. Population based data from the Swedish Myeloma Register. Nahi H et al. Eur J Haematol. 2017 May 22. doi: 10.1111/ejh.12907. [Epub ahead of print]. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. Salem DA et al. Leuk Lymphoma. 2017…
Haematological cancer: Pembrolizumab is effective in multiple myeloma. Sidaway P. Nat Rev Clin Oncol. 2017 May 23. doi: 10.1038/nrclinonc.2017.76. [Epub ahead of print]. A Phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractorymultiple myeloma. Martin T et al. Blood. 2017 May 8. pii: blood-2016-09-740787. doi: 10.1182/blood-2016-09-740787. [Epub ahead of print]. Pembrolizumab, pomalidomide and low dose dexamethasone for relapsed/refractory multiple myeloma.…
The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Thanendrarajan S et al. Haematologica. 2017 May 26. pii: haematol.2017.168872. doi: 10.3324/haematol.2017.168872. [Epub ahead of print]. Somatic mutation spectrum in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape compared to multiple myeloma. Mikulasova A et al. Haematologica. 2017 May 26.…
Experiences of establishing an academic early phase clinical trials unit. Brown SR et al. Clin Trials. 2017 May 1:1740774517710250. doi: 10.1177/1740774517710250. [Epub ahead of print]. Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy. Harousseau JL et al. J Clin Oncol. 2017 May 19:JCO2017731331. doi: 10.1200/JCO.2017.73.1331. [Epub ahead of print]. Race colors transplantation utilization for multiple myeloma. Majhail NS et al. Cancer. 2017 May…
Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy.
Rodrigues GH et al. Lasers Med Sci. 2017 May 16. doi: 10.1007/s10103-017-2211-0. [Epub ahead of print].
G-CSF improves safety when you start the day after autologous transplant in multiple myeloma.
Sborov DW et al. Leuk Lymphoma. 2017 May 16:1-5. doi: 10.1080/10428194.2017.1318436. [Epub ahead of print].
Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies. Jakubowiak AJ et al. Hematology. 2017 May 25:1-7. doi: 10.1080/10245332.2017.1328165. [Epub ahead of print]. Clinical conditions responsible for hyperviscosity and skin ulcers complications. Caimi G et al. Clin Hemorheol Microcirc. 2017 May 19. doi: 10.3233/CH-160218. [Epub ahead of print]. Increased risk of arterial thromboembolic events with combination…
Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously UntreatedMyeloma Patients Eligible for Transplants. Chen JF et al. Acta Haematol. 2017 May 5;137(4):207-208. doi: 10.1159/000471839. [Epub ahead of print]. Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV). Tessenow…
Serum free light chain quantitative assays: Dilemma of a biomarker. Cigliana G et al. J Clin Lab Anal. 2017 Apr 26. doi: 10.1002/jcla.22243. [Epub ahead of print]. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Milani P et al. Am J Hematol. 2017 Apr 25. doi: 10.1002/ajh.24772. [Epub ahead of print]. Heavy/light chain ratio for…